Skip to main content
Top
Published in: Pathology & Oncology Research 3/2020

01-07-2020 | Prostate Cancer | Review

Prognostic Differences in ISUP Grade Group 4: a Systematic Review and Meta-Analysis

Authors: Thomas Chengxuan Lu, Luke Collins, Penelope Cohen, Alex Jay, Jared M. Campbell, Michael O’Callaghan

Published in: Pathology & Oncology Research | Issue 3/2020

Login to get access

Abstract

The ISUP (Internal Society of Urologic Pathology) recently adopted a five-tiered prognostication system. There is evidence to suggest that the ISUP grade group 4 is a heterogeneous entity regarding prognosis. Our aim was to systematically examine the existing evidence to determine if outcome differences exist within the ISUP grade group 4. A systematic search of the literature for all studies examining the heterogeneity of the ISUP grade group 4 was conducted. Available studies were combined with meta-analysis to evaluate prognostic differences within the ISUP grade group 4 measured by all-cause mortality (ACM) and the prostate cancer-specific mortality (PCSM). Eight studies were identified and utilised a variety of outcome measures to answer the question of heterogeneity within the ISUP grade group 4. Four of these studies examined prognosis using both ACM and PCSM. These were combined into a meta-analysis. The combined group of 5 + 3/3 + 5 had statistically significant higher ACM (hazard ratio [HR] 1.23, 95% confidence internal [Cl] 1.08–1.41) when compared to the 4 + 4 group. There was no difference in the PCSM between the two groups (HR 1.34, 95% CI 0.89–2.01). However, heterogeneity was high for this analysis secondary to a range of methodological differences. Our meta-analysis showed that Gleason grade 3 + 5/5 + 3 had higher ACM than Gleason grade group 4 + 4. Measures of PCSM were statistically insignificant, although heterogeneity was high. Evidence suggests that heterogeneity is likely, although inconclusive. Further studies with consistent methodologies are required to answer this question.
Literature
1.
go back to reference Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR (2017) Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol 199:683–690. https://doi.org/10.1016/j.juro.2017.11.095 CrossRefPubMed Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR (2017) Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part I: risk stratification, shared decision making, and care options. J Urol 199:683–690. https://​doi.​org/​10.​1016/​j.​juro.​2017.​11.​095 CrossRefPubMed
2.
go back to reference Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR (2018) Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options. J Urol 199(4):990–997. https://doi.org/10.1016/j.juro.2018.01.002 CrossRefPubMed Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov DV, Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR (2018) Clinically localized prostate cancer: AUA/ASTRO/SUO guideline. Part II: recommended approaches and details of specific care options. J Urol 199(4):990–997. https://​doi.​org/​10.​1016/​j.​juro.​2018.​01.​002 CrossRefPubMed
3.
go back to reference Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228–1242CrossRefPubMed Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228–1242CrossRefPubMed
4.
go back to reference (NCCN) NCCN (2018) Clinical practice guidelines on prostate cancer (NCCN) NCCN (2018) Clinical practice guidelines on prostate cancer
6.
20.
21.
go back to reference van den Bergh RC, van der Kwast TH, de Jong J, Zargar H, Ryan AJ, Costello AJ, Murphy DG, van der Poel HG (2016) Validation of the novel International Society of Urological Pathology 2014 five-tier Gleason grade grouping: biochemical recurrence rates for 3+5 disease may be overestimated. BJU Int 118(4):502–505. https://doi.org/10.1111/bju.13478 CrossRefPubMed van den Bergh RC, van der Kwast TH, de Jong J, Zargar H, Ryan AJ, Costello AJ, Murphy DG, van der Poel HG (2016) Validation of the novel International Society of Urological Pathology 2014 five-tier Gleason grade grouping: biochemical recurrence rates for 3+5 disease may be overestimated. BJU Int 118(4):502–505. https://​doi.​org/​10.​1111/​bju.​13478 CrossRefPubMed
22.
go back to reference Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, Palapattu GS, Kunju LP, Mehra R, Feng FY (2013) Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer 119(18):3287–3294. https://doi.org/10.1002/cncr.28215 CrossRefPubMed Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, Palapattu GS, Kunju LP, Mehra R, Feng FY (2013) Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer 119(18):3287–3294. https://​doi.​org/​10.​1002/​cncr.​28215 CrossRefPubMed
23.
Metadata
Title
Prognostic Differences in ISUP Grade Group 4: a Systematic Review and Meta-Analysis
Authors
Thomas Chengxuan Lu
Luke Collins
Penelope Cohen
Alex Jay
Jared M. Campbell
Michael O’Callaghan
Publication date
01-07-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00632-1

Other articles of this Issue 3/2020

Pathology & Oncology Research 3/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine